ADVERSE REACTIONS SECTION.

ADVERSE REACTIONS. Adverse reactions of orphenadrine are mainly due to the mild anticholinergic action of orphenadrine, and are usually associated with higher dosage. Dryness of the mouth is usually the first adverse effect to appear. When the daily dose is increased, possible adverse effects include: tachycardia, palpitation, urinary hesitancy or retention, blurred vision, dilation of pupils, increased ocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness, hypersensitivity reactions, pruritus, hallucinations, agitation, tremor, gastric irritation, and rarely urticaria and other dermatoses. Infrequently, an elderly patient may experience some degree of mental confusion. These adverse reactions can usually be eliminated by reduction in dosage. Very rare cases of aplastic anemia associated with the use of orphenadrine tablets have been reported. No causal relationship has been established.

CONTRAINDICATIONS SECTION.

CONTRAINDICATIONS. Contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardiospasm (megaesophagus) and myasthenia gravis. Contraindicated in patients who have demonstrated previous hypersensitivity to the drug.

DESCRIPTION SECTION.

DESCRIPTION. Orphenadrine citrate is the citrate salt of orphenadrine (2-dimethylaminoethyl 2-methyl-benzhydryl ether citrate). It occurs as white, crystalline powder having bitter taste. It is practically odorless; sparingly soluble in water, slightly soluble in alcohol. Each orphenadrine citrate tablet contains 100 mg orphenadrine citrate, USP. Orphenadrine citrate tablets also contain ethylcellulose NF, povidone USP, lactose monohydrate NF, and magnesium stearate NF.

DOSAGE & ADMINISTRATION SECTION.

DOSAGE AND ADMINISTRATION. TABLETS: Adults-Two tablets per day; one in the morning and one in the evening.

HOW SUPPLIED SECTION.

HOW SUPPLIED. Tablets 100 mg-Each round, white, convex tablet imprinted with G on one side and 2011 on the other side.Bottles of 30 NDC 42549-559-30Bottles of 56 NDC 42549-559-56Bottles of 60 NDC 42549-559-60 Store at controlled room temperature 15 to 30C (59 to 86F).Dispense in tightly-closed, light-resistant container (USP).Manufactured by: Impax Laboratories, Inc.Hayward, California 94544Dist. by: Global PharmaceuticalsDivision of IMPAX Laboratories, Inc.Philadelphia, PA 19124GLOBAL(R)Rev. 01/00124-02Relabeling and Repackaging by:STAT Rx USA LLCGainesville, GA 30501.

INDICATIONS & USAGE SECTION.

INDICATIONS. Orphenadrine citrate is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculo-skeletal conditions. The mode of action of the drug has not been clearly identified, but may be related to its analgesic properties. Orphenadrine citrate does not directly relax tense skeletal muscles in man.

MECHANISM OF ACTION SECTION.

ACTIONS. The mode of therapeutic action has not been clearly identified, but may be related to its analgesic properties. Orphenadrine citrate also possesses anticholinergic actions.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL.

Orphenadrine Citrate Extended-Release Tablets 100 mgRx only. ORPHENADRINE ER 100 mg Label Image.

PRECAUTIONS SECTION.

PRECAUTIONS. Confusion, anxiety and tremors have been reported in few patients receiving propoxyphene and orphenadrine concomitantly. As these symptoms may be simply due to an additive effect, reduction of dosage and/or discontinuation of one or both agents is recommended in such cases.Orphenadrine citrate should be used with caution in patients with tachycardia, cardiac decompensation, coronary insufficiency, or cardiac arrhythmias.Safety of continuous long-term therapy with orphenadrine has not been established. Therefore, if orphenadrine is prescribed for prolonged use, periodic monitoring of blood, urine and liver function values is recommended.

PREGNANCY SECTION.

PREGNANCY. Pregnancy category CSafe use of orphenadrine citrate has not been established with respect to adverse effects upon fetal development. Therefore, orphenadrine citrate should be used in women of childbearing potential and particularly during early pregnancy only when in the judgement of the physician the potential benefits outweigh the possible hazards.

WARNINGS SECTION.

WARNINGS. Some patients may experience transient episodes of light-headedness, dizziness or syncope. Orphenadrine citrate may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving motor vehicle; ambulatory patients should therefore be cautioned accordingly.